secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001558370-24-004945
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences obtains exclusive license for orexin-2 receptor agonist from Bioprojet
--------------------------------------------------------------------------------

- Upfront fee $25.5M; development/regulatory milestones up to $127.5M, sales milestones up to $240M.
- Licensed compound is pre-clinical; IND expected H2 2025 for narcolepsy and other indications.
- Exclusive rights to develop, manufacture, commercialize in US and Latin America.
- Amended 2017 and 2022 LCAs with Bioprojet to remove exclusivity of efforts provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024004945/0001558370-24-004945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024004945/hrmy-20240406x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer